Browsing by Autor "Alfredo Abrego"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item type: Item ,
    Factores asociados al Síndrome de Burnout en estudiantes de dos facultades de medicina de Panamá
    (2025) Roberto Sáenz; Wilyerson Quintero; Alfredo Abrego; Dianelis Tejera; Edwin Zambrano; Héctor Montero; Gladys Batista; Gabriela Araya Medrano
    Objetivo: Determinar los factores asociados al Síndrome de Burnout(SB) por agotamiento en estudiantes de medicina que cursan niveles básicos, preclínico y clínico en la facultad de medicina de la Universidad de Panamá y Universidad Latina. Metodología: Los datos relevantes a los casos y controles de este estudio fueron obtenidos a través del método de encuesta, la cual fue respondida de manera anónima, de manera virtual a estudiantes de medicina de la Universidad de Panamá y Universidad LatinaResultados: Se obtienen 210 respuestas de la encuesta anónima, 52 positivos (grupo de casos) y 158 negativos (grupo de controles) para Síndrome de Burnout, y solo se seleccionaron los primeros 52 controles, con un total de 104 estudiantes de medicina. De los factores de riesgo en estudiantes con Síndrome de Burnout que más sobresalen destacan que el 84.62% habían fracasado exámenes, 90.38% habían considerado abandonar el curso y 94% cursaba sus estudios en universidad pública.Conclusiones: La aparición de Síndrome de Burnout en estudiantes de medicina se asoció con el fracaso de exámenes, las escasas horas de ejercicio semanal, las horas de estudio semanal y el tipo de universidad, siendo la asociación más relevante el considerar abandonar el curso. Se requieren estudios adicionales para evaluar y considerar las horas de sueño que llevan al burnout.
  • Thumbnail Image
    Item type: Item ,
    PATH-31. Prognostic impact of isocitrate dehydrogenase mutation on overall survival in gliomas: a retrospective analysis from Panama
    (Oxford University Press, 2025) Francisco Palma-Garcia; Alfredo Abrego; María Teresa Salgado; Andrew Neill; Raul Lorenzo-Luaces; Peter Chong; José Castillo; Rafaél Arauz
    Abstract INTRODUCTION Despite the recognized prognostic value of isocitrate dehydrogenase (IDH) mutations in gliomas, real-world survival data from low- and middle-income countries (LMICs), particularly in Latin America, are scarce. This study aimed to evaluate the prognostic impact of IDH mutation status on overall survival (OS) in a national cohort from Panama. MATERIALS AND METHODS We retrospectively analyzed 196 glioma patients diagnosed between 2018 and 2023 at the National Oncology Institute of Panama. Tumor histology and grade were classified according to the 2021 WHO Classification. IDH mutation status was assessed via immunohistochemistry. Patients with ependymoma or incomplete clinical records were excluded. Epidemiological variables, treatment modalities, tumoral and molecular characteristics were collected. Kaplan–Meier survival curves, log-rank tests, and Cox regression models were applied. Analyses were performed using SPSS 30.0. The study protocol was approved by the Bioethics Committee of The Panama Clinic (EC-CBITPC-063). RESULTS Among 196 patients, 59 (30%) were IDH-mutant and 137 (70%) IDH wild-type. Median OS was not reached for the IDH-mutant group but was 11.4 months (95% CI: 8.3–14.5) in the IDH wild-type group (p < 0.001). Median follow-up time was 34.23 months (95% CI: 25.9–42.5). A total of 123 patients (62.8%) died during follow-up. On multivariable analysis, age ≥ 65 years (HR 1.76; p = 0.008), biopsy-only procedure (HR 2.04; p = 0.004), and Karnofsky Index < 70% (HR 2.02; p = 0.010) predicted worse OS. IDH mutation (HR 0.25; p < 0.001) and frontal-lobe location (HR 0.61; p = 0.039) were associated with improved survival. CONCLUSION In this cohort, IDH mutation emerged as a strong independent predictor of OS. These findings support the routine implementation of IDH testing and expanded access to molecular diagnostics in glioma care across LMICs. Prospective studies are warranted to validate these results.